Fennec Pharmaceuticals Inc
FENC
Get informed when a big investor buys or sells
+ FollowMarket Cap$407.12M
Close$
$-11.22
193.1% downside
Current Fair Value
193.1% downsideOvervalued by 193.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $407.12 Million |
|---|---|
| Enterprise Value | $369.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.36 |
| Beta | 1.07 |
| Outstanding Shares | 34,545,000 |
Return
| Return on Equity | -8.69% |
|---|---|
| Return on Assets | -4.87% |
| Return on Invested Capital | -2.70% |
Valuation & Multiples
| P/E Ratio | -90.15 |
|---|---|
| PEG | 55.45 |
| Price to Sales | 12.06 |
| Price to Book Ratio | 12.06 |
| Enterprise Value to Revenue | 6.21 |
| Enterprise Value to EBIT | -215.77 |
| Enterprise Value to Net Income | -101 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$16.21 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$19.11 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.82%▼ 32.37% |
|---|---|
| Total Invested | $54.45M▼ 45.35% |
| Investors Holding | 33▼ 58.00% |
ESG Score
No data
About Fennec Pharmaceuticals Inc
CEO: Rostislav Raykov